CTOs on the Move

Structural

www.structural.com

 
Structural is pioneering Employee Success Management, by giving organizations real time, mobile access to their employee data. Structural integrates data from HR, business and personal systems, giving employees an internal resume to showcase their skills and interests, and helping leaders quickly find the right people with the right skills for sales pursuits, projects and strategic initiatives. With Structural, organizations form deeper connections, bust silos, engage and retain talent and drive growth. The company is the fifth to launch from leading venture studio High Alpha.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.structural.com
  • 55 Monument Circle Suite 201
    Indianapolis, IN USA 46204
  • Phone: 800.944.3087

Executives

Name Title Contact Details
Ron Lancaster
 Chief Technology Officer Profile

Similar Companies

ShopText

ShopText is a New York, NY-based company in the Software and Internet sector.

JumpStart

JumpStart is the ideal learning environment for kids with fun educational games, activities, worksheets & lesson plans for all grades. Get these online resources now!

Ventrino Software

Ventrino Software is a Bradenton, FL-based company in the Software and Internet sector.

Ariento

Secure, regulatory compliant IT starts here. Ariento is a leading B2B cybersecurity, information technology (IT), and compliance service provider. From consulting to fully outsourced services and more, Ariento gives business owners and executi...

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.